Compare OGN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | IMTX |
|---|---|---|
| Founded | 1923 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2020 |
| Metric | OGN | IMTX |
|---|---|---|
| Price | $13.75 | $9.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $11.40 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.6M | 489.8K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $1.67 | $25.91 |
| P/E Ratio | $14.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $5.05 |
| 52 Week High | $13.76 | $12.41 |
| Indicator | OGN | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.40 | 51.49 |
| Support Level | $13.46 | $9.37 |
| Resistance Level | N/A | $10.41 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 93.18 | 63.29 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.